Aurinia Pharmaceuticals Reports Q2 2026 Financial Results

What Happened
Aurinia Pharmaceuticals Inc. announced its financial results for the three months ended June 30, 2026 via a press release dated August 6, 2026. The company furnished that press release as Exhibit 99.1 to a Form 8-K filed on August 6, 2026 (Item 2.02: Results of Operations and Financial Condition). The Form 8-K was signed by Michael Hearne, Chief Financial Officer.

Key Details

• Reporting period: quarter ended June 30, 2026 (three months ended June 30, 2026).
• Press release dated August 6, 2026 furnished as Exhibit 99.1 to the Form 8-K.
• Form 8-K filed under Item 2.02 (results of operations and financial condition) and Item 9.01 (exhibits).
• Form 8-K was signed by CFO Michael Hearne on August 6, 2026.

Why It Matters
This filing publicly discloses Aurinia’s latest quarterly financial and operational results—key information investors use to assess recent revenue, earnings trends, cash position, and business progress. Retail investors should review the furnished press release and the company’s subsequent SEC filings for the detailed numbers (revenue, net income/loss, cash balance, guidance) referenced in the announcement.